NHS England Low Priority Treatment - Dronedarone by all CCGs

Why it matters: Dronedarone was originally approved to prevent recurrence of atrial fibrillation, or to lower the heart rate in adults who have had or have non-permanent atrial fibrillation. In September 2011 this indication was restricted to the maintenance of normal heart rhythm in ‘persistent’ or ‘paroxysmal’ atrial fibrillation after normal heart rhythm has been restored. NICE clinical guideline on Atrial Fibrillation puts greater emphasis on rate rather than rhythm control and has clarified the place of dronedarone in the treatment pathway.

Description: Cost of Dronedarone per 1000 patients

Performance: Loading...


Tagged as: Cost Saving, Cardiovascular system, NHS England Investment and Impact Fund, NHS England Low Priority, Cardiovascular system, NICE, Safety (or browse all measures)

CCGs are ordered by mean percentile over the past six months. Each chart shows the results for the individual CCG, plus deciles across all CCGs in the NHS in England.

View measure for NHS England combined →

Fetching data...

Do you need help with your analysis? We can often provide one-off custom extracts from our prescribing data for free. to find out more.